Clinical Trial Update: A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial to assess whether GSK256073A can block niacin-induced flushing in healthy volunteers and subjects with dyslipidemia; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• GSK256073A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Healthy Subjects, Dyslipidaemias | Phase 1 | Status: COMPLETED